Press monitoring
Gene drive mosquitoes engineered to fight malaria
25.11.2015 | Press monitoring
Mutant mosquitoes engineered to resist the parasite that causes malaria could wipe out the disease in some regions – for good. Humans contract malaria from mosquitoes that are infected by parasites from the genus Plasmodium. Previous work had shown that mosquitoes could be engineered to rebuff the parasite P. falciparum, but researchers lacked a...
Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled
24.11.2015 | Press monitoring
Paris and Tarrytown, New York - November 24, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular (CV) benefits of Praluent ® (alirocumab) Injection after an acute coronary syndrome...
Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
24.11.2015 | Press monitoring
OXFORD, United Kingdom and PHILADELPHIA, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with Stage IIIb or Stage IV...
Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
23.11.2015 | Press monitoring
Geneva, Switzerland, 23 November 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that it has been awarded a CHF666,240 grant from the Swiss Commission for Technology and Innovation (CTI) to advance the characterization of allosteric modulator...
Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis
23.11.2015 | Press monitoring
Basel, November 23, 2015 - Novartis announced today that the European Commission (EC) has approved Cosentyx ® (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor...
Salmon is first transgenic animal to win US approval for food
23.11.2015 | Press monitoring
A fast-growing salmon has become the first genetically engineered animal to be approved for human consumption in the United States. The decision, issued by the US Food and Drug Administration (FDA) on 19 November, releases the salmon from two decades of regulatory limbo. The move was met with swift opposition from some environmental and...
ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis
20.11.2015 | Press monitoring
Geneva, Switzerland, 20 November 2015 - ObsEva and Kissei Pharmaceutical Co., Ltd. ("Kissei") today announced that they have entered into a collaboration agreement to develop and commercialize KLH-2109 for the treatment of endometriosis and other potential indications. KLH-2109 is a novel, oral gonadotropin-releasing hormone (GnRH) antagonist,...
Sanofi and AstraZeneca Exchange More Than 200,000 Chemical Compounds
20.11.2015 | Press monitoring
Paris, France - November 20, 2015 - Sanofi and AstraZeneca today announced a direct exchange of 210,000 compounds from their respective, proprietary compound libraries. The exchange represents a novel, open innovation model of collaboration between two leading pharmaceutical companies. It will enhance the chemical diversity of the compound...
Introducing an algal carbon-concentrating mechanism into higher plants
20.11.2015 | Press monitoring
Crops with improved yields could more easily become a reality, thanks to a development by scientists. Researchers studying a biological process that enables tiny green algae to grow efficiently have taken the first steps to recreating the mechanism in a more complex plant. Their findings could lead to the breeding of high yield varieties of...
Targovax ASA: LUDWIG CANCER RESEARCH AND CANCER RESEARCH INSTITUTE PARTNER WITH TARGOVAX TO TEST CANDIDATE VIROTHERAPY IN EARLY-PHASE CLINICAL TRIALS
18.11.2015 | Press monitoring
November 18, 2015, New York, NY and Oslo, Norway - Ludwig Cancer Research and the Cancer Research Institute (CRI) announced today an agreement with the biotechnology company Targovax to evaluate its experimental virotherapy, ONCOS-102, in early phase clinical trials testing the virotherapy in combination with other, potentially synergistic...
